insulin detemir


Novo Nordisk


Firma Chun Cheong
Concise Prescribing Info
Insulin detemir (recombinant DNA origin)
DM in adults, adolescents & childn ≥1 yr.
Dosage/Direction for Use
SC In combination w/ oral antidiabetic agents or GLP-1 receptor agonists Initially 0.1-0.2 u/kg or 10 u in adult once daily.
May be taken with or without food: For patients treated w/ once daily regimen, administer w/ evening meal or at bedtime. For patients w/ bd dosing, the evening dose can be administered either w/ the evening meal or at bedtime or 12 hr after the morning dose.
Special Precautions
Risk of hyperglycaemia & diabetic ketoacidosis w/ inadequate dosing or discontinuation of treatment in patients w/ type 1 DM. Risk of hypoglycaemia w/ excessive insulin dose, omitted meal or unplanned, strenuous physical exercise. Change in usual warning symptoms of hypoglycaemia in patients w/ greatly improved blood glucose control eg, intensified therapy, & w/ longstanding diabetes. Concomitant illness, especially infections & feverish conditions; diseases in the kidney, liver, or affecting the adrenal, pituitary or thyroid gland. Transfer to another type or brand of insulin; change in strength, brand (manufacturer), type, origin (animal insulin, human insulin, insulin analogue) &/or method of manufacture (recombinant DNA vs. animal source insulin). Rotate inj site continuously to reduce or prevent inj site reactions. Patients w/ severe hypoalbuminaemia. Cases of CHF in combination w/ thiazolidinediones. May impair ability to drive & use machines. Pregnancy & lactation.
Adverse Reactions
Hypoglycaemia. Inj site reactions (eg, pain, redness, hives, inflammation, bruising, swelling & itching at inj site).
Drug Interactions
Reduced patient's insulin requirement w/ oral antidiabetics, GLP-1 receptor agonists, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulphonamides. Increased patient's insulin requirement w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. Masked symptoms of hypoglycaemia w/ β-blockers. Either increased or decreased insulin requirements w/ octreotide/lanreotide. Intensified or reduced hypoglycaemic effects w/ alcohol.
ATC Classification
A10AB01 - insulin (human) ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
Levemir pre-filled pen 100 U/mL
3 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in